Table 2.

HRs and 95% CIs for cancer-specific death in CRC subgroups based on CIMP and MSI screening status

NSHDSCRUMS
n (%)*HR (95% CI)n (%)*HR (95% CI)
UnivariateMultivariateUnivariateMultivariate
All cases
    CIMP-negative95 (50.0)11198 (51.6)11
    CIMP-low68 (35.8)1.83 (1.15-2.92)2.01 (1.20-3.37)139 (36.2)1.29 (0.88-1.88)1.48 (1.00-2.22)
    CIMP-high27 (14.2)1.41 (0.71-2.79)1.84 (0.87-3.89)47 (12.2)1.17 (0.68-2.04)1.10 (0.59-2.03)
MSS§
    CIMP-negative91 (54.8)11182 (58.3)11
    CIMP-low61 (36.7)1.83 (1.13-2.96)1.89 (1.12-3.21)119 (38.1)1.31 (0.87-1.96)1.45 (0.95-2.23)
    CIMP-high14 (8.4)3.80 (1.87-7.74)3.05 (1.40-6.63)11 (3.5)3.35 (1.60-7.06)1.38 (0.62-3.07)
MSI§
    CIMP-negative4 (16.7)112 (20.0)11
    CIMP-low7 (29.2)2.27 (0.23-22.01)14 (23.3)1.10 (0.27-4.46)3.87 (0.46-32.39)
    CIMP-high13 (54.2)0.35 (0.02-5.46)34 (56.7)0.70 (0.20-2.39)1.23 (0.13-11.23)
  • *Number of cases included in the survival analyses.

  • Adjusted for sex, age at diagnosis, tumor location, tumor stage, and adjuvant chemotherapy. p53 screening status and mucinous histology were also tested but did not meet the criteria for inclusion.

  • CIMP-negative, 0 genes hypermethylated; CIMP-low, 1 to 5 genes hypermethylated; CIMP-high, 6 to 8 genes hypermethylated.

  • §Cases lacking nuclear staining of tumor cells for at least one of MLH1, MSH2, MSH6, or PMS2 were considered to have a positive MSI screening status.

  • HRs are not shown for multivariate analyses of NSHDS cases with a positive MSI screening status because the low number of cases in each subgroup produced noninterpretable results.